Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609618 | 1.00 | GABRA1 (0.46) | GABRA1GABRB1ALDH1A1MAPK1HPGD | |
| SCHEMBL22409931 | 0.84 | ALDH1A1 (0.39) | GABRA1GABRB1ALDH1A1MAPK1HPGD | |
| SCHEMBL1396970 | 0.83 | ALDH1A1 (0.42) | GABRA1GABRB1ALDH1A1MAPK1HPGD | |
| SCHEMBL16962926 | 0.83 | ALDH1A1 (0.38) | GABRA1GABRB1ALDH1A1MAPK1HPGD | |
| SCHEMBL28954855 | 0.83 | ALDH1A1 (0.42) | GABRA1GABRB1ALDH1A1MAPK1HPGD | |
| SCHEMBL1397083 | 0.83 | ALDH1A1 (0.38) | GABRA1GABRB1ALDH1A1MAPK1HPGD | |
| SCHEMBL29901066 | 0.83 | ALDH1A1 (0.42) | GABRA1GABRB1ALDH1A1MAPK1HPGD | |
| SCHEMBL2413818 | 0.82 | MAPK1 (0.42) | GABRA1GABRB1ALDH1A1MAPK1LMNA | |
| SCHEMBL15459963 | 0.78 | GABRA1 (0.52) | GABRA1GABRB1ALDH1A1MAPK1HPGD | |
| SCHEMBL27542431 | 0.78 | ALDH1A1 (0.46) | GABRA1GABRB1ALDH1A1MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2025-12-09 | — | — | US | disclosed |
| WO-2024103400-A1 | POLYCYCLIC COMPOUND AS GPR75 ACTIVATOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 水木未来(北京)科技有限公司 | 2024-05-23 | — | — | WO | disclosed |
| US-20240076278-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-03-07 | — | — | US | disclosed |
| EP-4046991-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2022-08-24 | — | — | EP | disclosed |
| CN-108137515-B | Hydroxy triazine compound and medical use thereof | 日本烟草产业株式会社 | 2021-07-06 | — | — | CN | disclosed |
| US-20210024486-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20200165272-A1 | BORATE COMPOUND, AND SYNTHESIS METHOD THEREFOR AND USES THEREOF | CHENGDU ORIGIN BIOTECHNOLOGY LIMITED COMPANY (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| WO-2019020099-A1 | BORATE COMPOUND, AND SYNTHESIS METHOD THEREFOR AND USES THEREOF | 成都地奥九泓制药厂 | 2019-01-31 | — | — | WO | disclosed |
| EP-3339296-A1 | HYDROXYTRIAZINE COMPOUND AND MEDICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-1984322-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-7745477-B2 | Heteroaryl and benzyl amide compounds | HOFFMAN-LA ROCHE INC. (US) | 2010-06-29 | — | — | US | disclosed |
| CN-101379022-A | Benzamide and heteroarene derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| EP-1984322-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| WO-2007090748-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | GABRA1 1485/4885GABRB1 1476/4885ALDH1A1 4161/4885 |
| US-20210024486-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGS1, PTGIS, PTGES | GABRA1 4131/4885GABRB1 3653/4885ALDH1A1 618/4885 |
| US-20200165272-A1 | BORATE COMPOUND, AND SYNTHESIS METHOD THEREFOR AND USES THEREOF | PSMB11, PSMC5, SEM1 | GABRA1 585/4885GABRB1 641/4885ALDH1A1 3956/4885 |
| US-20240076278-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGS1, PTGIS, PTGES | GABRA1 4131/4885GABRB1 3653/4885ALDH1A1 618/4885 |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | CYP1B1, CYP4B1, ABCG2 | GABRA1 194/4885GABRB1 179/4885ALDH1A1 986/4885 |
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | PTGS1, PTGIS, PTGES | GABRA1 4131/4885GABRB1 3653/4885ALDH1A1 618/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | GABRA1 699/4885GABRB1 979/4885ALDH1A1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.